Cancer Genetics Inc (NASDAQ:CGIX) target price raised to $2.00, reported today by Zacks Investment Research
- Updated: January 11, 2017
Boasting a price of $1.85, Cancer Genetics Inc (NASDAQ:CGIX) traded 5.71% higher on the day. With the last stock price close up 3.76% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.04% over the date range. Cancer Genetics Inc has recorded a 50-day average of $1.48 and a two hundred day average of $1.78. Volume of trade was up over the average, with 460,959 shares of CGIX changing hands over the typical 117,184
Cancer Genetics Inc (NASDAQ:CGIX) had its price target upped to $2.00 by Zacks Investment Research in an issued report issued Wednesday January 11, 2017. The updated target price indicates a possible upside of 0.08% based on the company's most recent stock price close.
With a total market value of $0, Cancer Genetics Inc has with a one year low of $1.10 and a one year high of $3.35 .
A total of 3 equity analysts have released a research note on CGIX. Two equity analysts rating the company a strong buy, one equity analyst rating the company a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a consensus target price of $8.42.
General Information About Cancer Genetics Inc (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.